荧光偏振免疫法测定唾液苯妥英钠质量浓度的临床研究  

Clinical Observation and Study of Salivary DPH Levels Monitoried by Fluorescence Polarization Immuno Assay

作　　者：李泽宇[1] 马文娟[1] 刘建军[1] 齐晓飞[1] 王毅 刘栓娣 

机构地区：[1]内蒙古医学院第一附院神经内科,呼和浩特010050

出　　处：《中国神经免疫学和神经病学杂志》1999年第1期50-52,共3页Chinese Journal of Neuroimmunology and Neurology

摘　　要：目的研究服用苯妥英钠（DPH），癫痫（EP）患者唾液与血清中DPH浓度关系，探讨测定唾液中DPH浓度替代血药浓度的可行性。方法采用荧光偏振免疫法（FPIA）测定30例服用DPH的EP患者唾液及血清质量浓度，分析两者相关性。结果唾液与血清中DPH质量浓度呈正相关（r＝0．8909，P＜0．001），其平均值分别为（1．11±0．58）mg／L和8．85±0．73mg／L。唾液中DPH质量浓度在0．5～1．0mg／L之间，EP症状被控制者占20．3％，未控制者占16．7％；质量浓度高于2．1mg／L者出现毒性反应占10％；1．0～2．1mg／L者EP症状控制者占53％。结论FPIA测定唾液中DPH质量浓度有可能部分替代测定血清中DPH质量浓度的方法。The relation ship between the salivary and the blood Diphenylhydantoin (DPH) Levels in the epileptic (EP) patients with oral dosing DPH were studied. Methods The total number of patients was 30 cases, who had orally taken of DPH. The salivary DPH levels and the blood DPH levels were monitored by the TDX in fluorescence polarization immuno assay (FPIA). Results The positive correlation ship in both of the salivary DPH levels and of the blood DPH levels was found in the 30 cases (r=0. 8909, P<0. 001). The salivary DPH level and the blood DPH levels was (1. 1 ±0. 58) μg/mL and (8. 85±0. 73) μg/mL separately. While the salivary DPH levels was within the range of 0. 5-10 μg/mL the percentage of contr0lled patients with EP was 73. 3%. The uncontrolled ones was 16. 7%.While the salivary DPH levels exceed 2. 1 μg/mL. The percentage patients with toxic symptoms is 10%, of the factors affecting the salivary DPH levels include salivary thickness of the patients and combined use of other antiepilepsy drugs. Conclusion It is partly possible that the salivarg DPH levels monitored by the TDX in FPIA is used a substitute for the blood DPH levels monitored by the FPIA.

关 键 词：苯妥英钠 荧光偏振免疫法 癫痫 唾液 检测 

分 类 号：R742.1[医药卫生—神经病学与精神病学] R971.6[医药卫生—临床医学]